These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Current therapeutic strategy for multiple myeloma. Suzuki K Jpn J Clin Oncol; 2013 Feb; 43(2):116-24. PubMed ID: 23293370 [TBL] [Abstract][Full Text] [Related]
27. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma. Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241 [No Abstract] [Full Text] [Related]
28. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus doxorubicin and dexamethasone as induction therapy in previously untreated multiple myeloma patients. Buda G; Orciuolo E; Carulli G; Galimberti S; Ghio F; Cervetti G; Pelosini M; Petrini M Acta Haematol; 2013; 129(1):35-9. PubMed ID: 23107867 [TBL] [Abstract][Full Text] [Related]
29. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. Palumbo A; Gay F; Falco P; Crippa C; Montefusco V; Patriarca F; Rossini F; Caltagirone S; Benevolo G; Pescosta N; Guglielmelli T; Bringhen S; Offidani M; Giuliani N; Petrucci MT; Musto P; Liberati AM; Rossi G; Corradini P; Boccadoro M J Clin Oncol; 2010 Feb; 28(5):800-7. PubMed ID: 20048187 [TBL] [Abstract][Full Text] [Related]
30. Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients. Lee JH; Lee JH; Kim DY; Kim SD; Choi Y; Kang YA; Seol M; Lee KH Eur J Haematol; 2012 Jun; 88(6):478-84. PubMed ID: 22364526 [TBL] [Abstract][Full Text] [Related]
31. Intracranial multifocal dural involvement in multiple myeloma: case report and review of the literature. Méndez CE; Hwang BJ; Destian S; Mazumder A; Jagannath S; Vesole DH Clin Lymphoma Myeloma Leuk; 2010 Jun; 10(3):220-3. PubMed ID: 20511169 [TBL] [Abstract][Full Text] [Related]
32. [Bortezomib-based combination therapy for relapsed or refractory multiple myeloma]. Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H Zhonghua Nei Ke Za Zhi; 2008 Feb; 47(2):102-6. PubMed ID: 18683793 [TBL] [Abstract][Full Text] [Related]
33. Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Manier S; Barthelemy M; Fouquet G; Prod'homme C; Le Ray E; Samarcq P; Noel MP; Terriou L; Facon T; Cossment C; Boulanger F; Leleu X Leukemia; 2012 Dec; 26(12):2552-4. PubMed ID: 22627696 [No Abstract] [Full Text] [Related]
34. Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Witzens-Harig M; Waldherr R; Beimler J; Zeier M; Hansmann J; Ho AD; Goldschmidt H; Moehler T Ann Hematol; 2007 Dec; 86(12):927-30. PubMed ID: 17605010 [No Abstract] [Full Text] [Related]
35. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials. Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961 [TBL] [Abstract][Full Text] [Related]
36. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study. Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642 [TBL] [Abstract][Full Text] [Related]
37. Thalidomide plus dexamethasone as a maintenance therapy after autologous hematopoietic stem cell transplantation improves progression-free survival in multiple myeloma. Maiolino A; Hungria VT; Garnica M; Oliveira-Duarte G; Oliveira LC; Mercante DR; Miranda EC; Quero AA; Peres AL; Barros JC; Tanaka P; Magalhães RP; Rego EM; Lorand-Metze I; Lima CS; Renault IZ; Braggio E; Chiattone C; Nucci M; de Souza CA; Am J Hematol; 2012 Oct; 87(10):948-52. PubMed ID: 22730113 [TBL] [Abstract][Full Text] [Related]
38. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Kimby E; Sverrisdottir A; Elinder G Eur J Haematol; 2004 Apr; 72(4):292-5. PubMed ID: 15089769 [TBL] [Abstract][Full Text] [Related]
39. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial. Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322 [TBL] [Abstract][Full Text] [Related]
40. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Barlogie B; Anaissie E; van Rhee F; Haessler J; Hollmig K; Pineda-Roman M; Cottler-Fox M; Mohiuddin A; Alsayed Y; Tricot G; Bolejack V; Zangari M; Epstein J; Petty N; Steward D; Jenkins B; Gurley J; Sullivan E; Crowley J; Shaughnessy JD Br J Haematol; 2007 Jul; 138(2):176-85. PubMed ID: 17593024 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]